WO2009051217A1 - フェンタニル含有経皮吸収製剤 - Google Patents

フェンタニル含有経皮吸収製剤 Download PDF

Info

Publication number
WO2009051217A1
WO2009051217A1 PCT/JP2008/068836 JP2008068836W WO2009051217A1 WO 2009051217 A1 WO2009051217 A1 WO 2009051217A1 JP 2008068836 W JP2008068836 W JP 2008068836W WO 2009051217 A1 WO2009051217 A1 WO 2009051217A1
Authority
WO
WIPO (PCT)
Prior art keywords
fentanyl
percutaneous absorption
absorption preparation
containing percutaneous
once daily
Prior art date
Application number
PCT/JP2008/068836
Other languages
English (en)
French (fr)
Inventor
Naruhito Higo
Tetsurou Tateishi
Masaru Nakanishi
Takaaki Terahara
Hidenao Minami
Shigeo Ota
Nobuo Tsutsumi
Original Assignee
Hisamitsu Pharmaceutical Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co., Inc. filed Critical Hisamitsu Pharmaceutical Co., Inc.
Priority to JP2009538162A priority Critical patent/JP5535640B2/ja
Publication of WO2009051217A1 publication Critical patent/WO2009051217A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明の課題は、新たに、患者の負担の軽減されたフェンタニル含有経皮吸収製剤を提供することにある。本発明は、フェンタニルまたはその塩を含有する、１日１回投与用フェンタニル含有経皮吸収製剤、特に１日１回投与を繰り返し、定常状態に達した後の連続する３日間において、１日毎の血中フェンタニル濃度平均値により得られる標準偏差値／平均値が４０％以下である、前記の経皮吸収製剤などに関する。
PCT/JP2008/068836 2007-10-17 2008-10-17 フェンタニル含有経皮吸収製剤 WO2009051217A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009538162A JP5535640B2 (ja) 2007-10-17 2008-10-17 フェンタニル含有経皮吸収製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-270651 2007-10-17
JP2007270651 2007-10-17

Publications (1)

Publication Number Publication Date
WO2009051217A1 true WO2009051217A1 (ja) 2009-04-23

Family

ID=40567478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068836 WO2009051217A1 (ja) 2007-10-17 2008-10-17 フェンタニル含有経皮吸収製剤

Country Status (2)

Country Link
JP (1) JP5535640B2 (ja)
WO (1) WO2009051217A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012140407A (ja) * 2010-12-13 2012-07-26 Hisamitsu Pharmaceut Co Inc 経皮吸収促進剤、ならびにそれを含有する医薬組成物および貼付剤
JP2017538735A (ja) * 2014-12-19 2017-12-28 スリーエム イノベイティブ プロパティズ カンパニー フェンタニルを含む経皮薬物送達デバイス
WO2019079291A1 (en) 2017-10-17 2019-04-25 Lubrizol Advanced Materials, Inc. COMPOSITION AND DEVICE FOR ADMINISTERING ACTIVE AGENTS ON SKIN SURFACES
JP2019210253A (ja) * 2018-06-06 2019-12-12 久光製薬株式会社 フェンタニル含有貼付剤
JP2023009187A (ja) * 2018-06-06 2023-01-19 久光製薬株式会社 フェンタニル含有貼付剤
JP2023038287A (ja) * 2018-06-06 2023-03-16 久光製薬株式会社 フェンタニル含有貼付剤
JP2023041781A (ja) * 2018-06-06 2023-03-24 久光製薬株式会社 フェンタニル含有貼付剤
JP7260726B1 (ja) 2018-06-06 2023-04-18 久光製薬株式会社 フェンタニル含有貼付剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504977A (ja) * 1988-04-08 1991-10-31 シグナス　セラピューティック　システムズ フェンタニールの経皮投与用ラミネート複合体
JPH1045570A (ja) * 1996-05-13 1998-02-17 Hisamitsu Pharmaceut Co Inc フェンタニル含有経皮投与テープ製剤
JP2000044476A (ja) * 1998-07-31 2000-02-15 Toko Yakuhin Kogyo Kk フェンタニル含有経皮吸収投与マトリックス型貼付剤
JP2003137773A (ja) * 2001-10-31 2003-05-14 Hisamitsu Pharmaceut Co Inc 積層支持体を有する貼付剤
JP2004010552A (ja) * 2002-06-07 2004-01-15 Hisamitsu Pharmaceut Co Inc 貼付剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI296531B (en) * 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504977A (ja) * 1988-04-08 1991-10-31 シグナス　セラピューティック　システムズ フェンタニールの経皮投与用ラミネート複合体
JPH1045570A (ja) * 1996-05-13 1998-02-17 Hisamitsu Pharmaceut Co Inc フェンタニル含有経皮投与テープ製剤
JP2000044476A (ja) * 1998-07-31 2000-02-15 Toko Yakuhin Kogyo Kk フェンタニル含有経皮吸収投与マトリックス型貼付剤
JP2003137773A (ja) * 2001-10-31 2003-05-14 Hisamitsu Pharmaceut Co Inc 積層支持体を有する貼付剤
JP2004010552A (ja) * 2002-06-07 2004-01-15 Hisamitsu Pharmaceut Co Inc 貼付剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Hisamitsu Seiyaku News Release", 15 October 2007 (2007-10-15), Retrieved from the Internet <URL:http://www.hisamitsu.co.jp/company/pdf/HFT290_071015.pdf> [retrieved on 20081201] *
DONNER,B. ET AL.: "Long-term treatment of cancer pain with transdermal fentanyl", J PAIN SYMPTOM MANAGE, vol. 15, no. 3, 1998, pages 168 - 75 *
KINOMI YOMIYA ET AL.: "Opioid Chintsuyaku ni yoru Itami no Chiryo no Genjo to Tenbo", SYMPTOM MANAGEMENT IN CANCER PATIENTS, vol. 14, no. 2, 2003, pages 47 - 53 *
KORTE,W. ET AL.: "Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients", J PAIN SYMPTOM MANAGE, vol. 11, no. 3, 1996, pages 139 - 46 *
NAKAYAMA H. ET AL.: "Prediction of Serum Profile of Fentanyl after Repeated Application of Durotep Patch on Skin", JAPANESE JOURNAL OF THERAPEUTIC DRUG MONITORING, vol. 21, no. 3, 2004, pages 248 - 254 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012140407A (ja) * 2010-12-13 2012-07-26 Hisamitsu Pharmaceut Co Inc 経皮吸収促進剤、ならびにそれを含有する医薬組成物および貼付剤
JP2017538735A (ja) * 2014-12-19 2017-12-28 スリーエム イノベイティブ プロパティズ カンパニー フェンタニルを含む経皮薬物送達デバイス
WO2019079291A1 (en) 2017-10-17 2019-04-25 Lubrizol Advanced Materials, Inc. COMPOSITION AND DEVICE FOR ADMINISTERING ACTIVE AGENTS ON SKIN SURFACES
JP2019210253A (ja) * 2018-06-06 2019-12-12 久光製薬株式会社 フェンタニル含有貼付剤
JP7179501B2 (ja) 2018-06-06 2022-11-29 久光製薬株式会社 フェンタニル含有貼付剤
JP2023009187A (ja) * 2018-06-06 2023-01-19 久光製薬株式会社 フェンタニル含有貼付剤
JP7216867B2 (ja) 2018-06-06 2023-02-01 久光製薬株式会社 フェンタニル含有貼付剤
JP2023038287A (ja) * 2018-06-06 2023-03-16 久光製薬株式会社 フェンタニル含有貼付剤
JP2023041781A (ja) * 2018-06-06 2023-03-24 久光製薬株式会社 フェンタニル含有貼付剤
JP7253127B2 (ja) 2018-06-06 2023-04-05 久光製薬株式会社 フェンタニル含有貼付剤
JP7253126B2 (ja) 2018-06-06 2023-04-05 久光製薬株式会社 フェンタニル含有貼付剤
JP7260726B1 (ja) 2018-06-06 2023-04-18 久光製薬株式会社 フェンタニル含有貼付剤
JP2023059998A (ja) * 2018-06-06 2023-04-27 久光製薬株式会社 フェンタニル含有貼付剤

Also Published As

Publication number Publication date
JPWO2009051217A1 (ja) 2011-03-03
JP5535640B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
WO2009051217A1 (ja) フェンタニル含有経皮吸収製剤
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MY137477A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
WO2007128817A3 (en) Insulin derivative
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
EP2545939A3 (en) Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
WO2009032034A3 (en) Stabilized picoplatin dosage form
TNSN06030A1 (en) Substituted thiazole-benzoisothiazole dioxide derivavites, method for the production thereof and use of the same
NZ604662A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
MX2013011175A (es) Analogos de glucagon novedosos.
MY152172A (en) Therapeutic agent for diabetes
DK1778680T3 (da) Spirocykliske cyclohexaderivater
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
WO2006124413A3 (en) Methods for treating drug resistant cancer
MY153408A (en) Novel methods
EP1749517B8 (en) Stable pharmaceutical composition comprising linezolid form IV
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
TW200626133A (en) Oral medication for twice-daily administration
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2008130321A3 (en) Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08838602

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009538162

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08838602

Country of ref document: EP

Kind code of ref document: A1